# An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

> **NCT04305795** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Rakuten Medical, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Recurrent Head and Neck Squamous Cell Carcinoma
- Metastatic Head-and-neck Squamous-cell Carcinoma
- Locally Advanced Cutaneous Squamous Cell Carcinoma
- Metastatic Cutaneous Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** 200 mg Pembrolizumab
- **BIOLOGICAL:** 350 mg Cemiplimab
- **COMBINATION_PRODUCT:** ASP-1929 PIT

## Key facts

- **NCT ID:** NCT04305795
- **Lead sponsor:** Rakuten Medical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-21
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04305795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04305795, "An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04305795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*